Mischa de Ridder1, Pieter D de Veij Mestdagh1, Joris B W Elbers1, Arash Navran1, Charlotte L Zuur2,3, Ludi E Smeele2,3, Abrahim Al-Mamgani4. 1. Department of Radiation Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. 2. Department of Head and Neck Surgery, Netherlands Cancer Institute, Amsterdam, The Netherlands. 3. Department of Oral and Maxillofacial Surgery, Academic Medical Center, Amsterdam, The Netherlands. 4. Department of Radiation Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. a.almamgani@nki.nl.
Abstract
PURPOSE: Recurrent head and neck squamous cell carcinoma (HNSCC) after chemoradiation is a challenging clinical problem. Salvage surgery (SS) is often extensive and mutilating. Oncological outcomes of SS are relatively well known, but little is published about the course of disease after the first recurrence, especially in patients without salvage possibilities. The aim of this study was to analyze the course of disease in patients with recurrent HNSCC after chemoradiation. METHODS: We retrospectively analyzed and descriptively reported the disease course in 198 patients with recurrent HNSCC after chemoradiation in the time period after the first recurrence. We scored any type of event, salvage treatment, systemic treatment and overall survival (OS). RESULTS: Of the 198 patients with recurrent HNSCC, salvage surgery was attempted in 104 (53%). SS was more frequently given in patients with recurrent laryngeal cancer, isolated regional failure (p < 0.001) and HPV-positive disease (p = 0.09). The 2-year OS of the whole group was 31% and was significantly different by tumor site, type of failure and SS. HPV-positive disease and salvaged recurrences were significantly predictive for better survival. One third of that salvaged patients was still alive without second recurrence. Median survival in patients that received any palliative systemic treatment without surgery, compared to those were no treatment was given, was 6 and 3 months, respectively (p = 0.006). CONCLUSIONS: Main factors influencing the course of disease in recurrent HNSCC are the possibilities for SS and HPV-status. Therefore, SS should always be considered and discussed. In patients without possibilities for SS, overall survival is 3-6 months.
PURPOSE: Recurrent head and neck squamous cell carcinoma (HNSCC) after chemoradiation is a challenging clinical problem. Salvage surgery (SS) is often extensive and mutilating. Oncological outcomes of SS are relatively well known, but little is published about the course of disease after the first recurrence, especially in patients without salvage possibilities. The aim of this study was to analyze the course of disease in patients with recurrent HNSCC after chemoradiation. METHODS: We retrospectively analyzed and descriptively reported the disease course in 198 patients with recurrent HNSCC after chemoradiation in the time period after the first recurrence. We scored any type of event, salvage treatment, systemic treatment and overall survival (OS). RESULTS: Of the 198 patients with recurrent HNSCC, salvage surgery was attempted in 104 (53%). SS was more frequently given in patients with recurrent laryngeal cancer, isolated regional failure (p < 0.001) and HPV-positive disease (p = 0.09). The 2-year OS of the whole group was 31% and was significantly different by tumor site, type of failure and SS. HPV-positive disease and salvaged recurrences were significantly predictive for better survival. One third of that salvaged patients was still alive without second recurrence. Median survival in patients that received any palliative systemic treatment without surgery, compared to those were no treatment was given, was 6 and 3 months, respectively (p = 0.006). CONCLUSIONS: Main factors influencing the course of disease in recurrent HNSCC are the possibilities for SS and HPV-status. Therefore, SS should always be considered and discussed. In patients without possibilities for SS, overall survival is 3-6 months.
Entities:
Keywords:
Head and neck cancer; IMRT; Radiotherapy; Recurrence; VMAT
Authors: K Kian Ang; Jonathan Harris; Richard Wheeler; Randal Weber; David I Rosenthal; Phuc Felix Nguyen-Tân; William H Westra; Christine H Chung; Richard C Jordan; Charles Lu; Harold Kim; Rita Axelrod; C Craig Silverman; Kevin P Redmond; Maura L Gillison Journal: N Engl J Med Date: 2010-06-07 Impact factor: 91.245
Authors: Robert L Ferris; George Blumenschein; Jerome Fayette; Joel Guigay; A Dimitrios Colevas; Lisa Licitra; Kevin J Harrington; Stefan Kasper; Everett E Vokes; Caroline Even; Francis Worden; Nabil F Saba; Lara Carmen Iglesias Docampo; Robert Haddad; Tamara Rordorf; Naomi Kiyota; Makoto Tahara; Mark Lynch; Vijayvel Jayaprakash; Li Li; Maura L Gillison Journal: Oral Oncol Date: 2018-04-17 Impact factor: 5.337
Authors: S A Spencer; J Harris; R H Wheeler; M Machtay; C Schultz; W Spanos; M Rotman; R Meredith Journal: Int J Radiat Oncol Biol Phys Date: 2001-12-01 Impact factor: 7.038
Authors: M de Ridder; Z A R Gouw; J J Sonke; A Navran; B Jasperse; J Heukelom; M E T Tesselaar; W M C Klop; M W M van den Brekel; Abrahim Al-Mamgani Journal: Eur Arch Otorhinolaryngol Date: 2016-12-09 Impact factor: 2.503
Authors: James A Bonner; Paul M Harari; Jordi Giralt; Roger B Cohen; Christopher U Jones; Ranjan K Sur; David Raben; Jose Baselga; Sharon A Spencer; Junming Zhu; Hagop Youssoufian; Eric K Rowinsky; K Kian Ang Journal: Lancet Oncol Date: 2009-11-10 Impact factor: 41.316
Authors: William M Mendenhall; Charles M Mendenhall; Robert S Malyapa; Jatinder R Palta; Nancy P Mendenhall Journal: Am J Clin Oncol Date: 2008-08 Impact factor: 2.339
Authors: Corey J Langer; Jonathan Harris; Eric M Horwitz; Nicos Nicolaou; Merrill Kies; Walter Curran; Stuart Wong; Kian Ang Journal: J Clin Oncol Date: 2007-10-20 Impact factor: 44.544
Authors: Matthew C Ward; Nadeem Riaz; Jimmy J Caudell; Neal E Dunlap; Derek Isrow; Sara J Zakem; Joshua Dault; Musaddiq J Awan; John A Vargo; Dwight E Heron; Kristin A Higgins; Jonathan J Beitler; Samuel Marcrom; Drexell H Boggs; Comron Hassanzadeh; Chandana A Reddy; James A Bonner; Min Yao; Mitchell Machtay; Farzan Siddiqui; Andy M Trotti; Nancy Y Lee; Shlomo A Koyfman Journal: Int J Radiat Oncol Biol Phys Date: 2017-06-17 Impact factor: 8.013
Authors: Kaitlin M Christopherson; Amy C Moreno; Baher Elgohari; Neil Gross; Renata Ferrarotto; Abdallah Sherif Radwan Mohamed; G Brandon Gunn; Ryan P Goepfert; Frank E Mott; Shalin J Shah; C David Fuller; Jay P Reddy; Steven J Frank; William H Morrison; Jack Phan; David I Rosenthal; Adam S Garden Journal: Oral Oncol Date: 2020-12-22 Impact factor: 5.972
Authors: E Pérez-Islas; A García-Carrancá; E Acosta-Gio; N Reynoso-Noverón; H-A Maldonado-Martínez; M Guido-Jiménez; N Sobrevilla-Moreno; M Granados-García; W-B Pérez-Báez; D Vilar-Compte Journal: Med Oral Patol Oral Cir Bucal Date: 2022-03-01